Researchers reviewed how different types of immunotherapy work for people with recurrent pancreatic ductal adenocarcinoma. The review looked at several treatments, including immune checkpoint inhibitors, personalized vaccines, and specialized cell therapies like CAR-T and CAR-NK.
For most patients with this type of cancer, standard immune checkpoint inhibitors alone did not show consistent benefits when added to chemotherapy. However, these drugs showed more promise for a specific group of patients whose tumors have certain genetic markers known as MSI-H or dMMR.
Other advanced treatments, such as vaccines and engineered cell therapies, are still in the testing phase. These options are best studied in trials where patients are selected based on specific biomarkers. Because these treatments are investigational, they are not yet standard care for everyone. Patients should talk to their doctors about whether these targeted approaches might fit their specific diagnosis.
